Company OKYO Pharma Limited

EMMLD

GG00BMFG5F62

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Delayed Nasdaq Other stock markets 08:19:31 04/06/2024 pm IST			5-day change	1st Jan Change
1.432 ^USD	+0.12%		+9.25%	-19.11%

22/03	H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	MT
22/03	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	CI

OKYO Pharma Limited is a United Kingdom-based clinical stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The Company is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Number of employees: 8

Managers	Title	Age	Since
Gary Jacob CEO	Chief Executive Officer	77	07/21/07
Keeren Shah DFI	Director of Finance/CFO	47	01/20/01
William Clementi COO	Chief Operating Officer	-	01/23/01
Raj Patil CTO	Chief Tech/Sci/R&D Officer	66	21/18/21
Paul Spencer IRC	Investor Relations Contact	-	01/22/01

Members of the board	Title	Age	Since
John Brancaccio BRD	Director/Board Member	76	10/20/10
Willy Simon BRD	Director/Board Member	72	01/15/01
Gabriele Cerrone CHM	Chairman	52	07/21/07
Gary Jacob CEO	Chief Executive Officer	77	07/21/07
Bernard Denoyer BRD	Director/Board Member	77	01/21/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	25,519,882	186,793 ( 0.7320 %)	0	42.63 %
Stock B	0	33,780,850	25,092,455 ( 74.28 %)	0

Name	Equities	%	Valuation
Gabriele Cerrone 27.61 %	9,178,119	27.61 %	13 M $
Barclays Bank Plc 2.575 %	855,887	2.575 %	1 M $
Gary Jacob 0.1381 %	45,883	0.1381 %	66 393 $
G1 Execution Services LLC 0.0611 %	20,310	0.0611 %	29 389 $
John Brancaccio 0.0502 %	16,670	0.0502 %	24 121 $
Cerity Partners LLC 0.0401 %	13,312	0.0401 %	19 262 $
Geode Capital Management LLC 0.0364 %	12,090	0.0364 %	17 494 $
HSBC Bank Plc 0.0359 %	11,933	0.0359 %	17 267 $
Willy Simon 0.0269 %	8,948	0.0269 %	12 948 $
Continuum Advisory LLC 0.000150 %	50	0.000150 %	72 $

OKYO Pharma Ltd.

107 Cheapside 9th Floor

EC2V 6DN, London

+44 20 7495 2379

http://www.okyopharma.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.43 USD

Average target price

7 USD

Spread / Average Target

+389.51%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
OKYO PHARMA LIMITED	-19.11%	47.53M
CSL LIMITED	-1.62%	90.85B
SAMSUNG BIOLOGICS CO.,LTD.	-1.05%	39.02B
BIOGEN INC.	-10.43%	33.46B
BIOMARIN PHARMACEUTICAL INC.	-19.55%	14.51B
INCYTE CORPORATION	-6.18%	13.22B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.42%	11.65B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-47.67%	10.57B
SWEDISH ORPHAN BIOVITRUM AB	+6.52%	9.23B
ALTEOGEN INC.	+102.03%	7.71B

Biopharmaceuticals